Holen Sie sich die Stockscreener-App
35.73
0.93%
0.26
Schlusskurs vom Vortag:
$35.47
Offen:
$35.95
24-Stunden-Volumen:
1.86M
Relative Volume:
0.64
Marktkapitalisierung:
$4.13B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-359.64M
KGV:
-11.22
EPS:
-3.1831
Netto-Cashflow:
$-278.69M
1W Leistung:
+8.55%
1M Leistung:
+23.45%
6M Leistung:
+44.30%
1J Leistung:
+20.42%
1-Tages-Spanne:
$35.50
$37.50
1-Wochen-Bereich:
$32.51
$37.50
52-Wochen-Spanne:
$18.92
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
Firmenname
Viking Therapeutics Inc
Sektor
Branche
Telefon
858-704-4660
Adresse
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
35.75 | 4.10B | 0 | -359.64M | -278.69M | -3.1831 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.57 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
747.28 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.71 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.76 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.67 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Eingeleitet | Goldman | Neutral |
| 2025-02-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-07 | Eingeleitet | Citigroup | Neutral |
| 2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-22 | Eingeleitet | B. Riley Securities | Buy |
| 2024-11-04 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-11 | Eingeleitet | JP Morgan | Overweight |
| 2024-06-27 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-07 | Eingeleitet | Jefferies | Buy |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2023-05-31 | Fortgesetzt | ROTH MKM | Buy |
| 2023-03-28 | Bestätigt | Maxim Group | Buy |
| 2023-03-17 | Eingeleitet | Stifel | Buy |
| 2021-07-29 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-05-01 | Eingeleitet | BTIG Research | Buy |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-25 | Eingeleitet | Stifel | Buy |
| 2019-03-29 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Bestätigt | Maxim Group | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-18 | Bestätigt | Maxim Group | Buy |
| 2018-09-18 | Bestätigt | Raymond James | Outperform |
| 2018-07-20 | Eingeleitet | SunTrust | Buy |
| 2018-06-28 | Eingeleitet | Raymond James | Outperform |
| 2018-06-01 | Bestätigt | Laidlaw | Buy |
| 2018-05-31 | Bestätigt | Maxim Group | Buy |
| 2018-03-26 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-11-28 | Bestätigt | Maxim Group | Buy |
| 2017-11-21 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten
Viking Therapeutics Phase 3 Obesity Move Tests VK2735 Valuation Gap - Sahm
Is Viking Therapeutics (VKTX) Price Move Justified By DCF And Book Value Signals - Yahoo Finance
Jefferies Maintains Buy on Viking Therapeutics, Inc. (VKTX) March 2026 - Meyka
Jefferies reiterates Buy on Viking Therapeutic stock, $101 target - Investing.com
Can Viking Therapeutics Capitalize on Weight Loss Drugs for a Comeback? - NAI500
WINTON GROUP Ltd Buys Shares of 68,700 Viking Therapeutics, Inc. $VKTX - MarketBeat
Here's Why Viking Therapeutics Stock Recovered and Can Soar in 2026 - The Motley Fool
Here's Why Viking Therapeutics Stock Recovered and Can Soar 2026 - AOL.com
VKTX Stock Extends Red-Hot Streak: Insider Scoops Up Shares As Multiple Phase 3 Trials Loom This Year In Obesity Race - Stocktwits
How Viking Therapeutics Inc. (VKTX) Affects Rotational Strategy Timing - Stock Traders Daily
Insider Buying: Neil Aubuchon Acquires Shares of Viking Therapeu - GuruFocus
Management Purchase Signals Confidence in Viking Therapeutics' Pipeline - AD HOC NEWS
Viking Therapeutics (NASDAQ:VKTX) Insider Acquires $149,912.50 in Stock - MarketBeat
Viking Therapeutics Stock Gets RS Rating Upgrade - Investor's Business Daily
Viking Therapeutics at Leerink Conference: Strategic Moves in Obesity Market - Investing.com
2 Under-the-Radar Stocks to Buy and Hold - AOL.com
VKTX: Rapid progress in dual agonist obesity trials sets up major data and commercial milestones for 2026 - TradingView
VKTX: Phase 3 obesity trials advance rapidly, with pivotal data and new oral options expected in 2026 - TradingView
Is Viking Therapeutics (VKTX) One of the Shorted Biotech Stocks to Invest in - Yahoo Finance
Top 10 Takeover Targets of 2026GEN - GEN - Genetic Engineering and Biotechnology News
Forget AI Stocks: This Potentially Disruptive Biotech Could Soar By 181%, According to Wall Street - AOL.com
Viking Therapeutics, Inc. $VKTX Shares Purchased by Rhenman & Partners Asset Management AB - MarketBeat
Viking Therapeutics (VKTX) Valuation Check After Recent Share Price Swings And Analyst Fair Value Gap - Yahoo Finance
Viking Therapeutics, Inc. (NASDAQ:VKTX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is It Time To Reassess Viking Therapeutics (VKTX) After Its Recent Share Price Swings - simplywall.st
Assessing Viking Therapeutics (VKTX) Valuation After Sharp Swings And Obesity Drug Optimism - simplywall.st
Viking Therapeutics, Inc. (VKTX) Experiences a Steeper Decline Compared to the Overall Market: Important Takeaways - Bitget
Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Notable Two Hundred Day Moving Average CrossVKTX - Nasdaq
Biotech Viking Therapeutics heads to twin Miami investor conferences - Stock Titan
Viking Therapeutics Stock Soars To 10-Month High After Canaccord Boost – Retail Traders See It As Next Big Obesity Play - Stocktwits
Raymond James Lowers Viking Therapeutics, Inc. (VKTX) Price Target Amid Optimistic Clinical Initiative Outlook - Finviz
VKTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Viking Therapeutics, Inc. (VKTX) Stock Analysis: Exploring A 178% Upside Potential - DirectorsTalk Interviews
Viking Therapeutics (VKTX) Stock: Financial Performance Highlights 22% Revenue Growth and 44% Profit Increase in 2025 - MEXC
Viking Therapeutics, Inc. (VKTX) Stock: Revenue Surges 22% as Adjusted Net Income Jumps 44% in 2025 - MEXC
Rafferty Asset Management LLC Purchases 41,888 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat
Vanguard Group Reduces Stake in Viking Therapeutics - National Today
Viking Therapeutics, Inc.Common Stock (NQ: VKTX - The Chronicle-Journal
Viking Therapeutics, Inc. $VKTX Shares Sold by Vanguard Group Inc. - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Upgraded at BTIG Research - MarketBeat
Viking Therapeutics (VKTX) Is Up 9.1% After Advancing VK2735 As Rival Obesity Drug Stumbles - simplywall.st
Why the Market Dipped But Viking Therapeutics, Inc. (VKTX) Gained Today - Yahoo Finance
Viking Therapeutics: The High-Stakes Weight Loss Contender - MarketBeat
Viking Therapeutics Advances VK2735 As Obesity Data And Valuation Draw Focus - simplywall.st
Viking Therapeutics Gains Ground Amid Novo Nordisk's Clinical Setback - AD HOC NEWS
Is Viking Therapeutics (VKTX) Still Attractive After Its Recent Share Price Surge - Yahoo Finance
Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. - The Motley Fool
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125 - 富途牛牛
Viking Therapeutics Advances VK2735 As Phase 3 Trials Shape Valuation - simplywall.st
Viking Therapeutics Gains Momentum as Rival Stumbles - AD HOC NEWS
Finanzdaten der Viking Therapeutics Inc-Aktie (VKTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):